Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 10 May 2013 | By Alexander Gaffney, RAC,
The US Food and Drug Administration (FDA) has released a final guidance document that it says is intended to expedite the donation of blood and plasma for frequent donors.
The final guidance, "Implementation of an Acceptable Abbreviated Donor History Questionnaire and Accompanying Materials for Use in Screening Frequent Donors of Blood and Blood Components," recognizes a standard maintained by the American Association of Blood Banks (AABB) known as the abbreviated donor history questionnaire (aDHQ) version 1.3.
As least as far back as 2000, AABB said it wanted to support an abbreviated questionnaire for frequent donors as a means to expedite the donation process and make it less burdensome on donors. As anyone who has ever given blood can attest, the process of going through screening is exponentially longer than is the process of giving blood, which could potentially discourage people from donating blood as frequently.
"Such redundant questioning may discourage some frequent donors from returning for future donations," FDA explained in its 2013 guidance. "Streamlining of the donor screening process may enhance the availability of safe blood products from frequent donors."
But that raises an issue: How can you expedite the process while still being certain that someone is eligible to donate blood? Less thorough screening procedures represent something of a higher-risk, higher-reward paradigm in this respect. While donors might be more likely to give blood if a survey is shorter, they might also be more susceptible to omitting important information, thereby increasing the chance of a disease being transmitted through the blood product.
FDA has long recognized the potential benefits of an expedited donor history collection process. In July 2003, it issued a guidance document entitled, "Streamlining the Donor Interview Process: Recommendations for Self-Administered Questionnaires," which allowed blood establishments to permit "certain donors"-frequent ones-to undergo a simplified screening process.
Now FDA is implementing an updated version of the AABB's standard and outlining its appropriate use in its new final guidance document. "We find the AABB aDHQ documents (version 1.3) to be acceptable for use in screening frequent blood donors," FDA observed.
In it, the agency explains that any abbreviated questionnaire should be administered in conjunction with the full-length (FL) questionnaire. For example, if a company adopts the abbreviated questionnaire standard, it should also administer the FL questionnaire, and not a proprietary or other questionnaire that might not use the same wording as the abbreviated questionnaire.
The abbreviated documents in the aDHQ standard include the:
The new standard also differs from previous standards in that it eliminates several questions that AABB officials determined "would not need to be asked in future interviews" involving the donor.
Sponsors that choose to implement the aDHQ standard will be required to report its use to FDA under 21 CFR 601.12, typically under an annual report so long as they are implemented without modifications or without modifications that would be determined "important to the safety… of screening procedures." If such changes are made, the facility must submit FDA Form 356H to FDA, along with a cover letter explaining the changes and the new questionnaire containing highlighted changes.
In addition, if the questionnaire is administered to patients using a computer-assisted procedure, facilities need to submit a changes being effected 30-day (CBE-30) notice to FDA indicating how that system functions.
FDA's guidance also contains one caveat: The AABB questionnaire contains questions regarding the pregnancy status of the donor. FDA does not require this question to be asked under its regulations, and the agency said sponsors who omit the question will not be penalized or be found to be out of compliance with FDA requirements.
The guidance document may be found here, and its Federal Register notification may be found here.
Tags: Donation, guidance
Regulatory Focus newsletters
All the biggest regulatory news and happenings.